Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05659979 |
Other study ID # |
ITA7976 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 1, 2023 |
Est. completion date |
January 1, 2024 |
Study information
Verified date |
December 2022 |
Source |
University of Palermo |
Contact |
Nicola Veronese, MD |
Phone |
0916558519 |
Email |
nicola.veronese[@]unipa.it |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Osteoarthritis (OA) is the most common form of arthritis, and is characterized by joint pain
and stiffness leading to functional decline and relevant loss in quality of life. The
management of knee OA is demanded to several specialists, including general practitioners,
rheumatologists, orthopedics and finally geriatricians. However, the exact role of
geriatricians in the management of knee OA was poorly studied, whilst the comprehensive
geriatric assessment (CGA) is widely used for preventing negative consequences in older
people.
Description:
Osteoarthritis (OA) is the most common form of arthritis, and is characterized by joint pain
and stiffness leading to functional decline and relevant loss in quality of life. The
incidence of OA is rising due to the aging population and an increase in some risk factors,
such as obesity. Knee OA is the most common OA localization, and symptomatic knee OA is
highly prevalent among people aged over 50 years, affecting more than 250 million people
worldwide.
Knee OA is a leading cause of pain in older people, and pain of the hip and knee results in
physical disability and an increased risk of all-cause mortality. Hip and knee OA together
are the eleventh highest contributor to global disability: the years of life lived with
OA-related disability increased by 64% from 1990 to 2010 reaching 17 million. OA is a
progressive disorder, with different degrees of severity, that requires long-term management
with various treatment options over the course of the disease. The goals of treatment for OA
are to reduce symptoms and ultimately slow disease progression, which may in turn reduce the
impact of OA on the patient's mobility and quality of life, with consequent reduction in
healthcare resource needs.
In 2019, the European Society for Clinical and Economic Aspects of Osteoporosis,
Osteoarthritis and Musculoskeletal Diseases (ESCEO) published recommendations for the
management of knee OA in the form of a treatment algorithm that provides practical guidance
for the prioritization of interventions and guides physicians through progressive, logical
steps based on the severity of the knee OA signs/symptoms.
The management of knee OA is therefore demanded to several specialists, including general
practitioners, rheumatologists, orthopedics and finally geriatricians. However, the exact
role of geriatricians in the management of knee OA was poorly studied, whilst the
comprehensive geriatric assessment (CGA) is widely used for preventing negative consequences
in older people, such as hospitalization or mortality. Moreover, CGA can be used across
different settings, from primary care to hospital, with similar beneficial effects in older
people. Finally, people affected by knee OA are usually affected by other medical (e.g.,
dementia, cardiovascular diseases, depression) and non-medical (e.g., loneliness) conditions
that can limit the adherence to therapeutic approaches, therefore limiting the efficacy of
the interventions suggested in knee OA.